First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
about
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancerImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsEpidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issuesCurrent management of metastatic brain diseaseEGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.Management of patients with advanced non-small cell lung cancer: role of gefitinibErlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancerA phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.Gefitinib in non small cell lung cancerEGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistryErlotinib in the treatment of advanced non-small cell lung cancer: an update for cliniciansComprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan.Personalized medicine and treatment approaches in non-small-cell lung carcinoma.Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).Epidermal growth factor receptor inhibition and non-small cell lung cancer.Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancerClinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersPharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statementCetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyGefitinib for the treatment of non-small-cell lung cancer.Gefitinib in the treatment of advanced non-small-cell lung cancer.Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.BMP-4 genetic variants and protein expression are associated with platinum-based chemotherapy response and prognosis in NSCLC.Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments.Pharmacotherapy targeting the EGFR oncogene in NSCLC.Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis.Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer.Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
P2860
Q21198843-101DCE86-4959-435A-9A17-E670F7229520Q24625201-9E25BB0C-3FFC-495B-B3C4-7B6EFA7B58D4Q24653036-93F682AC-A34C-49F4-BE87-701BF9E3049BQ33475484-7E9C35AF-A481-4F54-812E-9ED7DB3D232AQ33574958-FE58A865-F2AE-4DAE-B24E-640288F8C204Q33892597-62C33DE9-336E-4DFF-8B1D-8D6676F5AF5AQ34159240-6B67364A-9535-488F-AA87-DB41625711C2Q34571839-95F625F1-361E-47DE-B631-6879B9393094Q35031807-AC5B6717-9855-4126-9C12-F72A0C77C2C0Q35164306-30BA4A72-E152-4F9F-BF72-FB05D51A150EQ35628121-1194E971-3FF6-4568-BFA1-CA02312F2370Q36194473-B999C904-2D44-4E9F-8065-49354E73566FQ36441548-0C9B6B20-9A7D-4576-B9B3-C7EDBCCAA864Q36494159-77A67B35-9955-4B90-BD29-838B019689ECQ36504349-AC22DEA0-ABEA-4BDB-B705-A0CF1E2644E9Q36612451-36B34500-DFD3-46EB-935A-CB165C991F5DQ36628704-666F383B-454B-4D57-8B24-5E0D956026D6Q36905639-1B5D2D86-A843-4362-B7E3-AB530F573C45Q36966043-16CBFBC2-C9EC-4AD1-975A-259DCEB52A2FQ37102068-B4F863ED-EF44-4467-8AB3-65A92489121DQ37282841-3CC78EBB-327F-42DD-9A1C-0E958FD3BF2FQ37347532-17B6EEB9-2FD7-4A6A-8301-A8EAE7821943Q37357287-124F2B8E-9999-4AEE-BF34-3E91EFC39309Q37449013-A1F1D94A-23D4-44C0-8397-082BD3660CBAQ37645161-F4240A57-88B4-4197-AC7B-73473D18AD32Q37688183-EA6036AB-90D9-46AE-8844-8A5230F79C57Q37701147-2F95794C-0964-4495-9D53-62D3DD293BB7Q37724215-E7EF77B9-F82F-4299-B307-55526DA41D25Q38088215-F58F9DEE-3397-415B-B3D1-B32E5D779BA7Q38248997-CFA72270-4225-438E-8D3A-83662CD6A8A7Q38289406-BF9C61DD-F4AD-4F65-B50D-BDEC69EE5046Q38770028-47497B10-9C5D-428A-9217-23A1BF357156Q40041019-FA7BF381-FB86-4DEC-AC4F-04CEE08E328AQ40177381-61ADDE4A-71D9-457B-9F35-44749B44A1C4Q41860438-E45080A6-A0FD-4F33-9C85-93E8A8307227Q44456952-688E9645-FE86-4601-8EC6-8D85E845B1CAQ48100116-97290EA1-EB0B-4DA8-B109-6BCC6A110A54Q51011218-76346C99-48B0-4278-8397-E2F47B99ACC0
P2860
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
First-line single agent treatm ...... lung cancer: a phase II study.
@en
First-line single agent treatm ...... lung cancer: a phase II study.
@nl
type
label
First-line single agent treatm ...... lung cancer: a phase II study.
@en
First-line single agent treatm ...... lung cancer: a phase II study.
@nl
prefLabel
First-line single agent treatm ...... lung cancer: a phase II study.
@en
First-line single agent treatm ...... lung cancer: a phase II study.
@nl
P2093
P356
P1476
First-line single agent treatm ...... lung cancer: a phase II study.
@en
P2093
Hironobu Ohmatsu
Kaoru Kubota
Kiyotaka Yoh
Koichi Goto
Nagahiro Saijo
Ryutaro Kakinuma
Seiji Niho
Yutaka Nishiwaki
P356
10.1200/JCO.2005.02.5825
P407
P577
2006-01-01T00:00:00Z